PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27372432-3 2016 METHODS: Sixteen subjects with mild allergic asthma were recruited to a two-period cross-over study: one treatment period with the selective COX-2 inhibitor etoricoxib and one without. Etoricoxib 157-167 prostaglandin-endoperoxide synthase 2 Homo sapiens 141-146 25828692-2 2016 The pre-emptive and postoperative analgesic effects of the cyclooxygenase-2 inhibitor etoricoxib have been investigated using a 2 x 2 factorial trial design. Etoricoxib 86-96 prostaglandin-endoperoxide synthase 2 Homo sapiens 59-75 27372432-10 2016 CONCLUSIONS: Short-term treatment with the COX-2 inhibitor etoricoxib had a minor impact on T-cell responses, supporting its safe use also in subjects exposed to triggers of lymphocyte activation. Etoricoxib 59-69 prostaglandin-endoperoxide synthase 2 Homo sapiens 43-48 26548623-7 2015 Some other COX-2 inhibitors, such as, apricoxib and etoricoxib are under critical investigation currently. Etoricoxib 52-62 prostaglandin-endoperoxide synthase 2 Homo sapiens 11-16 22882551-1 2013 BACKGROUND: Etoricoxib, a selective inhibitor of cyclooxygenase 2, is increasingly used in pain relief. Etoricoxib 12-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 49-65 25340915-4 2014 COX-2 inhibitors include drugs such as celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib. Etoricoxib 73-83 prostaglandin-endoperoxide synthase 2 Homo sapiens 0-5 23652751-0 2013 Increased risk for complications after colorectal surgery with selective cyclo-oxygenase 2 inhibitor etoricoxib. Etoricoxib 101-111 prostaglandin-endoperoxide synthase 2 Homo sapiens 73-90 21618455-11 2011 The selective cyclooxygenase 2 (COX-2) inhibitor etoricoxib was a more potent inductor of LUF syndrome than nonselective COX inhibitors. Etoricoxib 49-59 prostaglandin-endoperoxide synthase 2 Homo sapiens 14-30 23126318-4 2012 Etoricoxib is a specific cyclooxygenase 2 inhibitor with strong anti-inflammatory effects and a favorable pharmacokinetic profile for the management of inflammatory disorders. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 25-41 21618455-11 2011 The selective cyclooxygenase 2 (COX-2) inhibitor etoricoxib was a more potent inductor of LUF syndrome than nonselective COX inhibitors. Etoricoxib 49-59 prostaglandin-endoperoxide synthase 2 Homo sapiens 32-37 21235334-2 2011 This study was conducted to evaluate the clinical efficacy of two selective cyclooxygenase-2 inhibitors, celecoxib and etoricoxib, on pain prevention after periodontal surgery. Etoricoxib 119-129 prostaglandin-endoperoxide synthase 2 Homo sapiens 76-92 21332932-0 2011 Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo. Etoricoxib 125-135 prostaglandin-endoperoxide synthase 2 Homo sapiens 26-43 21457143-0 2011 Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3). Etoricoxib 58-68 prostaglandin-endoperoxide synthase 2 Homo sapiens 31-47 21457143-3 2011 In this study, we evaluated the inhibitory effects of selective cyclooxygenase-2 inhibitor etoricoxib on hOAT3 by uptake experiments using Xenopus laevis oocytes. Etoricoxib 91-101 prostaglandin-endoperoxide synthase 2 Homo sapiens 64-80 20039959-5 2010 We hypothesized that etoricoxib, another Cox-2 inhibitor with a longer half-life, would also be effective in preventing fasting headache. Etoricoxib 21-31 prostaglandin-endoperoxide synthase 2 Homo sapiens 41-46 18823299-2 2008 The aim was to investigate whether the cyclooxygenase-2 selective nonsteroidal anti-inflammatory drug etoricoxib affects the steady-state pharmacokinetics of digoxin. Etoricoxib 102-112 prostaglandin-endoperoxide synthase 2 Homo sapiens 39-55 20584877-2 2010 In the present prospective, randomized, double-blind study we compared pain management with a selective (COX-2) inhibitor (etoricoxib) with pain management using sustained-release tramadol after elective hallux valgus surgery. Etoricoxib 123-133 prostaglandin-endoperoxide synthase 2 Homo sapiens 105-110 20877132-6 2010 For other cyclooxygenase-2 inhibitors celecoxib, etoricoxib, rofecoxib and valdecoxib, slight to moderate inhibition of hOAT3 only was observed. Etoricoxib 49-59 prostaglandin-endoperoxide synthase 2 Homo sapiens 10-26 20052461-8 2010 PGE(2) production in tissue was significantly blocked by the COX-2 inhibitor starting with the appearance of etoricoxib in tissue and lasting for the whole observation period of 24 h (P < 0.01). Etoricoxib 109-119 prostaglandin-endoperoxide synthase 2 Homo sapiens 61-66 19338584-10 2009 Furthermore, in HeLa cells after induction of COX2 by tumour necrosis factor alpha and subsequent PGE(2) release, inhibition of COX2 by etoricoxib did not affect HAS expression or HA secretion. Etoricoxib 136-146 prostaglandin-endoperoxide synthase 2 Homo sapiens 128-132 18952694-6 2009 Under this inflammatory condition, the COX-2 inhibitors DFU (1 micromol/L), DuP-697 (0.5 micromol/L), and Etoricoxib (1 micromol/L) markedly restored and increased the vascular reactivity to NE. Etoricoxib 106-116 prostaglandin-endoperoxide synthase 2 Homo sapiens 39-44 19392653-1 2009 Cyclooxygenase-2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers, including colon cancer, and therefore the potential ability of a selective COX-2 inhibitor, etoricoxib, is considered in the prevention of the 1,2-dimethyl hydrazine (DMH)-induced colon carcinogenesis in the rat model. Etoricoxib 202-212 prostaglandin-endoperoxide synthase 2 Homo sapiens 0-16 19392653-1 2009 Cyclooxygenase-2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers, including colon cancer, and therefore the potential ability of a selective COX-2 inhibitor, etoricoxib, is considered in the prevention of the 1,2-dimethyl hydrazine (DMH)-induced colon carcinogenesis in the rat model. Etoricoxib 202-212 prostaglandin-endoperoxide synthase 2 Homo sapiens 18-23 18823986-0 2008 Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Etoricoxib 99-109 prostaglandin-endoperoxide synthase 2 Homo sapiens 61-78 17697449-1 2007 BACKGROUND: Etoricoxib is a cyclooxygenase-2 (COX-2) selective inhibitor effective in the treatment of rheumatoid arthritis. Etoricoxib 12-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 28-44 18661871-1 2008 Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 16-32 18661871-1 2008 Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 34-39 18661871-1 2008 Etoricoxib is a cyclooxygenase 2 (COX-2) inhibitor that selectively inhibits the COX-2 enzyme and decreases the incidences of side effects associated with these agents. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 81-86 18405470-0 2008 Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Etoricoxib 109-119 prostaglandin-endoperoxide synthase 2 Homo sapiens 0-16 18405470-1 2008 OBJECTIVES: To review the clinical effectiveness and cost-effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA) and rheumatoid arthritis (RA). Etoricoxib 201-211 prostaglandin-endoperoxide synthase 2 Homo sapiens 75-91 18405470-1 2008 OBJECTIVES: To review the clinical effectiveness and cost-effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA) and rheumatoid arthritis (RA). Etoricoxib 201-211 prostaglandin-endoperoxide synthase 2 Homo sapiens 93-98 18516314-2 2007 One particular NSAID, which is a highly selective cyclo-oxygenase 2 inhibitor, etoricoxib, may be superior to standard NSAIDs for AS. Etoricoxib 79-89 prostaglandin-endoperoxide synthase 2 Homo sapiens 50-67 18443385-1 2008 Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 53-69 18443385-1 2008 Etoricoxib is presently the most commonly prescribed cyclooxygenase-2 (Cox-2) inhibitor for chronic pain and inflammatory conditions. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 71-76 17697449-1 2007 BACKGROUND: Etoricoxib is a cyclooxygenase-2 (COX-2) selective inhibitor effective in the treatment of rheumatoid arthritis. Etoricoxib 12-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 46-51 17155937-2 2007 Etoricoxib is a new cyclo-oxygenase-2 inhibitor with a long duration of action and a lack of a deteriorating effect on platelet function. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 20-37 17915794-1 2007 Diclofenac sodium, a non-selective cyclo-oxygenase inhibitor and etoricoxib, a selective cyclo-oxygenase-2 inhibitor have been widely used in treatment of patients with osteo-arthritis. Etoricoxib 65-75 prostaglandin-endoperoxide synthase 2 Homo sapiens 89-106 17915794-4 2007 The study shows that etoricoxib provides better clinical efficacy and gastro-intestinal tolerability in osteo-arthritis in comparison to diclofenac sodium presumably due to the selective inhibition of cyclo-oxygenase-2 by etoricoxib. Etoricoxib 21-31 prostaglandin-endoperoxide synthase 2 Homo sapiens 201-218 17915794-4 2007 The study shows that etoricoxib provides better clinical efficacy and gastro-intestinal tolerability in osteo-arthritis in comparison to diclofenac sodium presumably due to the selective inhibition of cyclo-oxygenase-2 by etoricoxib. Etoricoxib 222-232 prostaglandin-endoperoxide synthase 2 Homo sapiens 201-218 17278926-8 2007 For treatment of gouty inflammation, etoricoxib (a new cyclooxygenase 2 inhibitor) has been shown to be as effective as indomethacin. Etoricoxib 37-47 prostaglandin-endoperoxide synthase 2 Homo sapiens 55-71 16892790-0 2006 Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Etoricoxib 10-20 prostaglandin-endoperoxide synthase 2 Homo sapiens 33-49 17228166-3 2007 Our aim was to investigate the clinical tolerability of etoricoxib, a new selective cyclooxygenase-2 inhibitor, in a group of patients with well-established NSAID hypersensitivity. Etoricoxib 56-66 prostaglandin-endoperoxide synthase 2 Homo sapiens 84-100 16875903-3 2006 The MEDAL program is designed to provide a precise estimate of the relative cardiovascular event rates with the COX-2 selective inhibitor etoricoxib in comparison to the traditional NSAID diclofenac in patients with osteoarthritis and rheumatoid arthritis. Etoricoxib 138-148 prostaglandin-endoperoxide synthase 2 Homo sapiens 112-117 17304885-2 2007 OBJECTIVE: To evaluate tolerance to etoricoxib, a new cyclooxygenase-2 inhibitor, in NSAID-sensitive patients with urticaria-type adverse reactions. Etoricoxib 36-46 prostaglandin-endoperoxide synthase 2 Homo sapiens 54-70 17304885-6 2007 CONCLUSIONS: Etoricoxib, like other cyclooxygenase-2 inhibitors, is a well-tolerated drug in most NSAID-sensitive patients. Etoricoxib 13-23 prostaglandin-endoperoxide synthase 2 Homo sapiens 36-52 17691996-7 2007 This review examines the role of the newest COX-2 selective inhibitors, etoricoxib and lumiracoxib, in treating rheumatic disease. Etoricoxib 72-82 prostaglandin-endoperoxide synthase 2 Homo sapiens 44-49 16892790-3 2006 OBJECTIVES: To study the safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, and to determine whether it cross-reacts with asthma in patients with aspirin-exacerbated respiratory disease (AERD). Etoricoxib 35-45 prostaglandin-endoperoxide synthase 2 Homo sapiens 58-74 16397127-5 2006 Selective inhibition of cyclooxygenase 2-dependent prostacyclin (by rofecoxib or etoricoxib) was associated with increased urinary excretion of 11-dehydro-TXB(2) in carriers of TLR4 polymorphisms, but not in wild-type, suggesting a restrainable effect of prostacyclin on platelet function in vivo in this setting. Etoricoxib 81-91 prostaglandin-endoperoxide synthase 2 Homo sapiens 24-40 16136765-0 2005 Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Etoricoxib 10-20 prostaglandin-endoperoxide synthase 2 Homo sapiens 28-44 16192529-1 2005 UNLABELLED: In this randomized, double-blind, placebo-controlled, multicenter study we assessed the analgesic effect of etoricoxib (a new cyclooxygenase-2 inhibitor) in patients having had knee or hip replacement surgery. Etoricoxib 120-130 prostaglandin-endoperoxide synthase 2 Homo sapiens 138-154 16054359-2 2005 The potential of this methodology has been demonstrated by the successful radiosynthesis of carbon-11 analogues of several highly selective cyclooxygenase-2 (COX-2) inhibitors such as Rofecoxib, Etoricoxib, and 3-(4-methylsulfonylphenyl)-4-phenyl-5-trifluoromethyl isoxazole in high yield. Etoricoxib 195-205 prostaglandin-endoperoxide synthase 2 Homo sapiens 140-156 16054359-2 2005 The potential of this methodology has been demonstrated by the successful radiosynthesis of carbon-11 analogues of several highly selective cyclooxygenase-2 (COX-2) inhibitors such as Rofecoxib, Etoricoxib, and 3-(4-methylsulfonylphenyl)-4-phenyl-5-trifluoromethyl isoxazole in high yield. Etoricoxib 195-205 prostaglandin-endoperoxide synthase 2 Homo sapiens 158-163 16136765-3 2005 OBJECTIVE: To investigate the clinical tolerance of NSAID-sensitive individuals to the selective COX-2 inhibitors etoricoxib and celecoxib. Etoricoxib 114-124 prostaglandin-endoperoxide synthase 2 Homo sapiens 97-102 16049609-1 2005 INTRODUCTION: Etoricoxib is a second generation cyclooxygenase-2 inhibitor with a rapid-onset time and a long duration of action. Etoricoxib 14-24 prostaglandin-endoperoxide synthase 2 Homo sapiens 48-64 15815733-5 2005 RESULTS: Rofecoxib and the novel COX-2 inhibitors etoricoxib and valdecoxib have a higher degree of COX-2 selectivity than traditional NSAIDs. Etoricoxib 50-60 prostaglandin-endoperoxide synthase 2 Homo sapiens 100-105 15827069-0 2005 Etoricoxib: a highly selective COX-2 inhibitor. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 31-36 15827069-1 2005 OBJECTIVE: To review the available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that is not currently approved for use in the US. Etoricoxib 135-145 prostaglandin-endoperoxide synthase 2 Homo sapiens 166-182 15827069-1 2005 OBJECTIVE: To review the available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor that is not currently approved for use in the US. Etoricoxib 135-145 prostaglandin-endoperoxide synthase 2 Homo sapiens 184-189 15815733-5 2005 RESULTS: Rofecoxib and the novel COX-2 inhibitors etoricoxib and valdecoxib have a higher degree of COX-2 selectivity than traditional NSAIDs. Etoricoxib 50-60 prostaglandin-endoperoxide synthase 2 Homo sapiens 33-38 15818702-1 2005 OBJECTIVE: To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX-2) selective inhibitor, administered continuously over 52 weeks for the treatment of ankylosing spondylitis (AS). Etoricoxib 63-73 prostaglandin-endoperoxide synthase 2 Homo sapiens 77-93 15818702-1 2005 OBJECTIVE: To assess the efficacy, safety, and tolerability of etoricoxib, a cyclooxygenase 2 (COX-2) selective inhibitor, administered continuously over 52 weeks for the treatment of ankylosing spondylitis (AS). Etoricoxib 63-73 prostaglandin-endoperoxide synthase 2 Homo sapiens 95-100 15664353-1 2005 A simple, sensitive and specific HPLC method with UV detection (284 nm) was developed and validated for quantitation of Etoricoxib in human plasma, the newest addition to the group of nonsteroidal anti-inflammatory drugs-a highly selective cyclooxygenase-2 inhibitor. Etoricoxib 120-130 prostaglandin-endoperoxide synthase 2 Homo sapiens 240-256 15473012-1 2005 A practicable and selective liquid chromatography-mass spectrometry assay for the determination of two cyclooxygenase-2 inhibitors, etoricoxib and valdecoxib, in human plasma is presented. Etoricoxib 132-142 prostaglandin-endoperoxide synthase 2 Homo sapiens 103-119 14517196-1 2003 The effect of hepatic insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was investigated following administration of single and multiple oral doses to mild hepatic insufficiency patients (Child-Pugh score of 5 to 6), multiple oral doses to moderate hepatic insufficiency patients (Child-Pugh score of 7 to 9), and single intravenous doses to both mild and moderate hepatic insufficiency patients. Etoricoxib 63-73 prostaglandin-endoperoxide synthase 2 Homo sapiens 100-116 15701208-0 2004 Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Etoricoxib 115-125 prostaglandin-endoperoxide synthase 2 Homo sapiens 88-104 14681341-1 2004 The effect of renal insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was examined in 23 patients with varying degrees of renal impairment (12 moderate [creatinine clearance between 30 and 50 mL/min/1.73 m2], 5 severe [creatinine clearance below 30 mL/min/1.73 m2], and 6 with end-stage renal disease requiring hemodialysis) following administration of single 120-mg oral doses of etoricoxib. Etoricoxib 61-71 prostaglandin-endoperoxide synthase 2 Homo sapiens 98-114 15638077-1 2004 Etoricoxib is a potent and novel selective inhibitor of cyclooxygenase-2 (COX-2) which has been developed for the treatment of osteoarthritis, rheumatoid arthritis and several other inflammatory conditions. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 56-72 15638077-1 2004 Etoricoxib is a potent and novel selective inhibitor of cyclooxygenase-2 (COX-2) which has been developed for the treatment of osteoarthritis, rheumatoid arthritis and several other inflammatory conditions. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 74-79 15319795-1 2004 Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 72-88 15319795-1 2004 Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 90-95 15319795-1 2004 Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. Etoricoxib 12-19 prostaglandin-endoperoxide synthase 2 Homo sapiens 72-88 15319795-1 2004 Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. Etoricoxib 12-19 prostaglandin-endoperoxide synthase 2 Homo sapiens 90-95 12534404-0 2003 Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Etoricoxib 98-108 prostaglandin-endoperoxide synthase 2 Homo sapiens 60-77 12705971-1 2003 The validation of a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for the determination of the selective cyclooxygenase-2 inhibitor etoricoxib in human plasma with phenazone as internal standard is described. Etoricoxib 151-161 prostaglandin-endoperoxide synthase 2 Homo sapiens 124-140 12638395-0 2003 Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. Etoricoxib 46-56 prostaglandin-endoperoxide synthase 2 Homo sapiens 83-99 12638395-1 2003 The single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, were examined in two clinical studies. Etoricoxib 50-60 prostaglandin-endoperoxide synthase 2 Homo sapiens 87-103 12534404-2 2003 AIM: To assess the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib vs. non-selective non-steroidal anti-inflammatory drugs. Etoricoxib 88-98 prostaglandin-endoperoxide synthase 2 Homo sapiens 50-67 12077033-1 2002 OBJECTIVE: To assess the safety and efficacy of etoricoxib, a selective cyclo-oxygenase-2 inhibitor, in comparison with indometacin in the treatment of acute gouty arthritis. Etoricoxib 48-58 prostaglandin-endoperoxide synthase 2 Homo sapiens 72-89 12180720-1 2002 OBJECTIVE: To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA). Etoricoxib 112-122 prostaglandin-endoperoxide synthase 2 Homo sapiens 77-93 12180720-1 2002 OBJECTIVE: To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA). Etoricoxib 112-122 prostaglandin-endoperoxide synthase 2 Homo sapiens 95-100 11835200-0 2002 Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS. Etoricoxib 62-72 prostaglandin-endoperoxide synthase 2 Homo sapiens 80-96 11160644-0 2001 Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 100-116 11583479-0 2001 Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. Etoricoxib 29-39 prostaglandin-endoperoxide synthase 2 Homo sapiens 60-76 11353749-0 2001 Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Etoricoxib 59-69 prostaglandin-endoperoxide synthase 2 Homo sapiens 79-95 11353749-1 2001 Etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, was shown to be metabolized via 6"-methylhydroxylation (M2 formation) when incubated with NADPH-fortified human liver microsomes. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 35-51 11160644-3 2001 Using the ratio of IC(50) values (COX-1/COX-2), the selectivity ratio for the inhibition of COX-2 by etoricoxib in the human whole blood assay was 106, compared with values of 35, 30, 7.6, 7.3, 2.4, and 2.0 for rofecoxib, valdecoxib, celecoxib, nimesulide, etodolac, and meloxicam, respectively. Etoricoxib 101-111 prostaglandin-endoperoxide synthase 2 Homo sapiens 40-45 11160644-3 2001 Using the ratio of IC(50) values (COX-1/COX-2), the selectivity ratio for the inhibition of COX-2 by etoricoxib in the human whole blood assay was 106, compared with values of 35, 30, 7.6, 7.3, 2.4, and 2.0 for rofecoxib, valdecoxib, celecoxib, nimesulide, etodolac, and meloxicam, respectively. Etoricoxib 101-111 prostaglandin-endoperoxide synthase 2 Homo sapiens 92-97 11160644-9 2001 In summary, etoricoxib represents a novel agent that selectively inhibits COX-2 with 106-fold selectivity in human whole blood assays in vitro and with the lowest potency of inhibition of COX-1 compared with other reported selective agents. Etoricoxib 12-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 74-79 11160644-1 2001 We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration. Etoricoxib 42-52 prostaglandin-endoperoxide synthase 2 Homo sapiens 190-206 11160644-1 2001 We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration. Etoricoxib 42-52 prostaglandin-endoperoxide synthase 2 Homo sapiens 208-213 11160644-1 2001 We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration. Etoricoxib 54-61 prostaglandin-endoperoxide synthase 2 Homo sapiens 190-206 11160644-1 2001 We report here the preclinical profile of etoricoxib (MK-0663) [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], a novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2), that has been developed for high selectivity in vitro using whole blood assays and sensitive COX-1 enzyme assays at low substrate concentration. Etoricoxib 54-61 prostaglandin-endoperoxide synthase 2 Homo sapiens 208-213 11160644-2 2001 Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an IC(50) value of 1.1 +/- 0.1 microM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC(50) value of 116 +/- 8 microM for COX-1 (serum thromboxane B2 generation after clotting of the blood). Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 33-38 11160644-2 2001 Etoricoxib selectively inhibited COX-2 in human whole blood assays in vitro, with an IC(50) value of 1.1 +/- 0.1 microM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC(50) value of 116 +/- 8 microM for COX-1 (serum thromboxane B2 generation after clotting of the blood). Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 124-129 33730601-5 2021 This article introduces a potential repositioning of the existing drug etoricoxib, which may inhibit cytokine storm to treat COVID-19 through reducing the activity of Cyclooxygenase-2 in the conversion of arachidonic acid to prostaglandin. Etoricoxib 71-81 prostaglandin-endoperoxide synthase 2 Homo sapiens 167-183 34811370-2 2021 Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-label phase I/II clinical trial (TBCOX2, NCT02503839). Etoricoxib 141-151 prostaglandin-endoperoxide synthase 2 Homo sapiens 103-119 32303303-1 2020 Etoricoxib, a selective inhibitor of cyclooxygenase-2, is used in the treatment of many inflammatory diseases and dental pain in humans. Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 37-53 33429006-5 2021 Treatment with a COX-2 selective inhibitor, etoricoxib, decreased PGE2, IL-6, MCP-1, and CLS-B formation as well as reduced aromatase protein and estrogen levels in the mammary tissue of mice fed a HSF diet. Etoricoxib 44-54 prostaglandin-endoperoxide synthase 2 Homo sapiens 17-22 32912981-13 2020 CONCLUSION: Although cyclo-oxygenase-2 inhibitors and traditional non-selective NSAIDs may be equally beneficial in terms of pain relief, cyclo-oxygenase-2 inhibitors (especially etoricoxib) may confer a greater benefit. Etoricoxib 179-189 prostaglandin-endoperoxide synthase 2 Homo sapiens 138-155 33468439-3 2021 Nonsteroidal anti-inflammatory drugs are one of the most common offending drug groups in FDE; however, selective cyclooxygenase-2 inhibitors, such as etoricoxib, are rarely implicated. Etoricoxib 150-160 prostaglandin-endoperoxide synthase 2 Homo sapiens 113-129 31190596-1 2019 Background: Etoricoxib is a second-generation cyclooxygenase-2-inhibitor approved in 2012 for short-term treatment of pain associated with dental surgery. Etoricoxib 12-22 prostaglandin-endoperoxide synthase 2 Homo sapiens 46-62 31360199-14 2019 Colchicine could upregulate miR-223-3p and downregulate IL-1beta in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2. Etoricoxib 86-96 prostaglandin-endoperoxide synthase 2 Homo sapiens 155-160 30080442-2 2019 Here, the molecular interaction between purified human hemoglobin (HHb), a major heme protein and etoricoxib, a cyclooxygenase-2 inhibitor was studied by various spectroscopic, calorimetric, and molecular modeling techniques. Etoricoxib 98-108 prostaglandin-endoperoxide synthase 2 Homo sapiens 112-128 28425581-9 2017 Treatment with etoricoxib, a selective cyclooxygenase-2 inhibitor, was proved to be beneficial and safe. Etoricoxib 15-25 prostaglandin-endoperoxide synthase 2 Homo sapiens 39-55 28954205-1 2018 Etoricoxib is a selective cyclooxygenase-2 inhibitor, with a lower risk of gastrointestinal toxicity compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Etoricoxib 0-10 prostaglandin-endoperoxide synthase 2 Homo sapiens 26-42 28464042-4 2017 Patients in each of the two study groups were randomized to receive 90 mg qd of the cyclooxygenase-2 inhibitor etoricoxib for six months, two weeks or to a control arm, respectively. Etoricoxib 111-121 prostaglandin-endoperoxide synthase 2 Homo sapiens 84-100